Vical Incorporated: Vical Reports Third Quarter 2014 Financial Results and …

Vical Incorporated: Vical Reports Third Quarter 2014 Financial Results and …

The Company's Phase 1/2 trial of its therapeutic vaccine designed to reduce the frequency and magnitude of viral shedding and reduce genital lesion recurrences in herpes simplex virus type 2 (HSV-2) positive subjects is progressing according to plan.

6
Like
Save

Comments

Comments are disabled for this post.